SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?

Affiliations

¹ Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, Centre Hospitalier Universitaire Liège, and Division of Clinical Pharmacology, Center for Interdisciplinary Research on Medicines, Liège University, B-4000 Liège, Belgium.

Comment

André J Scheen. Lancet Diabetes Endocrinol. 2019 Nov.

. 2019 Nov;7(11):818-820.

doi: 10.1016/S2213-8587(19)30310-9. Epub 2019 Sep 17.

¹ Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, Centre Hospitalier Universitaire Liège, and Division of Clinical Pharmacology, Center for Interdisciplinary Research on Medicines, Liège University, B-4000 Liège, Belgium.

No abstract available

Comment on

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, Thielke D, Viljoen A, McCrimmon RJ. Lingvay I, et al. Lancet Diabetes Endocrinol. 2019 Nov;7(11):834-844. doi: 10.1016/S2213-8587(19)30311-0. Epub 2019 Sep 17. Lancet Diabetes Endocrinol. 2019. PMID: 31540867 Clinical Trial.